WhatsApp

Adjusting Chemotherapy Dose by Muscle Mass May Reduce Nerve Damage in Colon Cancer Patients

You are here >> Home > Latest Updates > Colon Cancer Updates > Adjusting Chemotherapy…

Adjusting Chemotherapy Dose by Muscle Mass May Reduce Nerve Damage in Colon Cancer Patients

For patients with stage III colon cancer, chemotherapy with oxaliplatin after surgery is a standard treatment. While effective, oxaliplatin often causes nerve damage (neuropathy), leading to numbness, tingling, or pain in the hands and feet. These side effects can be long-lasting and affect daily life.

A new clinical trial called LEANOX tested whether adjusting the oxaliplatin dose based on a patient’s lean body mass (muscle mass), rather than just body size, could lower the risk of nerve damage.

In the study, patients with low muscle mass were split into two groups: one received the usual dose based on body size, while the other received a lower dose adjusted to their muscle mass.

The results showed that patients who received the muscle mass-based dose had far fewer cases of serious nerve problems. About two-thirds of these patients avoided significant neuropathy, compared with less than half in the standard dosing group. They also needed fewer dose cuts, tolerated more chemotherapy, and reported a better quality of life.

Importantly, adjusting the dose did not affect survival. Patients in both groups lived just as long and had the same chance of staying cancer-free after treatment.

This study suggests that tailoring chemotherapy doses to muscle mass could protect patients from one of the most disabling side effects of oxaliplatin, without reducing its effectiveness.

Rate this post
Dr. Harsh J Shah